DC-CIK细胞生物疗法联合化疗治疗中晚期非小细胞肺癌的近期临床效果研究

Short-term Clinical Efficacy of DC-CIK Cell Biotherapv Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

目的探讨DC-CIK细胞生物联合常规化疗治疗中晚期非小细胞肺癌的近期临床效果。方法选取2014年1月-2015年6月大连市第五人民医院收治的86例非小细胞肺癌患者,依据治疗方案的不同将患者分为对照组和观察组各43例。对照组应用常规化疗方案,观察组在常规化疗方案基础上联合应用DC-CIK细胞生物疗法。对比两组患者的近期临床效果,治疗前后血清肿瘤标志物、免疫功能指标及用药期间的不良反应发生情况。结果治疗后观察组总有效率为53.5%高于对照组的30.2%,差异具有统计学意义(χ^2=4.778,P<0.05)。治疗后两组TNF-α、CD4+、CD4+/CD8+水平均有所改善,且观察组改善程度优于对照组,差异具有统计学意义(t值分别为4.378,5.095和4.336,P值均<0.05)。治疗期间不良反应发生率观察组39.53%、对照组34.88%,观察组率略高于对照组但差异无统计学意义(χ^2=0.199,P〉0.05)。结论DC-CIK细胞生物疗法联合常规化疗治疗非小细胞肺癌的近期疗效优于单纯化疗,能够改善患者免疫水平,且不会增加不良反应,具有较好临床应用价值。

Objective To investigate the short-term clinical effect of DC-CIK cell biothcrapy combined with conventional chemotherapy in the treatment of advanced non-small cell lung cancer.Methods A total of 86 patients with non-small cell lung cancer admitted to the Fifth People's Hospital of Dalian from January 2014 to June 2015 were selected and divided into control group and observation group,43 cases in each group according to different treatment regimen.The control group was treated with conventional chemotherapy,while the observation group was treated with DC-CIK cell biotherapy on the basis of conventional chemotherapy.The short-term clinical effects,serum tumor markers,immune function indexes and adverse reactions were compared between the two groups before and after treatment.Results After treatment,the total effective rate of the observation group was 53.5%,and was significantly higher than 30.2%of the control group(χ^2=4.778,PV0.05).After treatment,the levels of TNF-α,CD4+,CD4+/CD8+in the two groups were significantly improved,and the improvement degree in the observation group was significantly better than that of the control group(t=4.378,5.095 and 4.336,P<0.05).The incidence of adverse reactions during treatment was 39.53%in the observation group and 34.88%in the control group.The incidcnce of adverse reactions in the observation group was slightly higher than that in the control group,but there was no significant difference(χ^2=0.199,P>0.05).Conclusion DC-CIK cell biotherapy combined with conventional chemotherapy for non-small cell lung cancer has better short-term efficacy than chemotherapy alone.It can improve the immune level of patients without increasing adverse rcactions and has better clinical application value.